SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Patience David

(Last)

(First)

(Middle)

C/O ACCELERATE DIAGNOSTICS, INC.

3950 S. COUNTRY CLUB ROAD, SUITE 470

(Street)

TUCSON

85714

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2023

3. Issuer Name and Ticker or Trading Symbol
Accelerate Diagnostics, Inc [ AXDX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	47,471	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Restricted Stock Units	⁽¹⁾	⁽²⁾	Common Stock	29,780	⁽³⁾	D
Employee Restricted Stock Units	⁽⁴⁾	⁽²⁾	Common Stock	25,000	⁽³⁾	D
Employee Stock Option (right to buy)	⁽⁵⁾	11/08/2027	Common Stock	22,500	$18.8	D
Employee Stock Option (right to buy)	⁽⁶⁾	03/07/2028	Common Stock	516	$25.95	D
Employee Stock Option (right to buy)	⁽⁷⁾	01/01/2029	Common Stock	18,113	$11.5	D
Employee Stock Option (right to buy)	⁽⁸⁾	01/01/2029	Common Stock	45,000	$11.5	D
Employee Stock Option (right to buy)	⁽⁹⁾	01/01/2030	Common Stock	15,161	$16.9	D
Employee Stock Option (right to buy)	⁽¹⁰⁾	03/24/2030	Common Stock	10,000	$5.93	D
Employee Stock Option (right to buy)	⁽¹¹⁾	03/24/2030	Common Stock	3,575	$5.93	D
Employee Stock Option (right to buy)	⁽¹²⁾	04/16/2030	Common Stock	10,000	$8.36	D
Employee Stock Option (right to buy)	⁽¹³⁾	03/07/2032	Common Stock	40,000	$2.34	D

Explanation of Responses:

1. The reporting person received an aggregate of 39,707 restricted stock units on March 13, 2021, which will vest in equal monthly amounts over 22 months. As of the date of this Form 3, 9,927 restricted stock units have vested leaving the remaining 29,780 restricted stock units to vest over the remain vesting period. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

2. Not applicable.

3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

4. The reporting person received 25,000 restricted stock units on February 26, 2022, of which 40% vests on February 26, 2024 and the remaining 60% will vest on February 26, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

5. On September 8, 2022, the stock option became fully vested and exercisable.

6. On March 7, 2018, the stock option became fully vested and exercisable.

7. On September 30, 2019, the stock option became fully vested and exercisable.

8. On January 1, 2023, the stock option became fully vested and exercisable.

9. On September 30, 2020, the stock option became fully vested and exercisable.

10. The reporting person received 10,000 stock options on March 24, 2020, which will vest in equal annual amounts every year over five years. As of the date of this Form 3, 6,000 stock options have vested and the remaining 4,000 stock options are set to vest over the remaining vesting period.

11. On March 24, 2020, the stock option became fully vested and exercisable.

12. On April 16, 2022, the stock option became fully vested and exercisable.

13. The reporting person received 40,000 stock options on March 7, 2022, of which 40% vests on March 7, 2024 and the remaining 60% will vest on March 7, 2025.

Remarks:

	/s/ David Patience	04/04/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.